Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare population analytics platform for health plans and ACOs; risk stratification, HEDIS quality measures, and predictive models for value-based care management.
Quadrant Health is a healthcare data analytics and decision support platform helping health plans, providers, and healthcare analytics teams manage population health, identify care gaps, and optimize clinical and financial performance. The company provides tools for risk stratification, utilization management, and quality measure tracking that help healthcare organizations identify high-cost patients, predict future utilization, and intervene proactively to improve outcomes and reduce unnecessary spending.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.